缺氧选择性前药物通过触发线粒和诱导亡来抑制瘤细胞
Fangjie Wang1, Lairong Song2, Qianqian Xu3
1Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou, Henan, 450018, China.
European journal of medicinal chemistry
|December 10, 2024
概括
一种新型的缺氧激活前药物CHD-1通过损害线粒体和诱导亡来选择性向并消除缺氧瘤细胞. 这种有针对性的方法在临床前模型中显示毒性降低,为低氧瘤治疗提供了一个有希望的策略.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 缺氧在固体瘤中很普遍,降低了治疗效率并促进了耐药性.
- 瘤缺氧是选择性药物输送和激活的治疗标.
研究的目的:
- 开发和评估CHD-1,一种针对癌症向治疗的新型缺氧激活前药物.
- 在临床前模型中评估CHD-1的疗效和毒性概况.
主要方法:
- 低氧激活前药物CHD-1的合成和表征.
- 实验室研究评估CHD-1对缺氧细胞与正常细胞中的线粒体功能和亡的影响.
- 在体内评估CHD-1在抑制HeLa异种移植生长中的有效性及其在动物模型中的急性毒性.
主要成果:
- 在低氧条件下选择性激活CHD-1,抑制瘤细胞生长.
- 治疗CHD-1损害了缺氧细胞中的线粒体形态和膜潜力,诱导了线粒细胞衰变和亡.
- 在体内研究表明,CHD-1显著抑制瘤生长,并与母分子相比具有有利的毒性概况.
结论:
- CHD-1是一种有前途的缺氧激活前药物,具有针对缺氧细胞的选择性抗瘤活性.
- 这种前药物具有降低的毒性概况,表明在低氧瘤治疗中具有临床开发潜力.
相关概念视频
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Electron Transport Chain: Complex I and II
11.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.5K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Autophagic Cell Death
3.4K
Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K


